Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Systemic methotrexate exposure is greater after intrathecal than after oral administration.

Bostrom BC, Erdmann GR, Kamen BA.

J Pediatr Hematol Oncol. 2003 Feb;25(2):114-7.

PMID:
12571461
2.

Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.

Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA.

Blood. 1998 Nov 15;92(10):3569-77.

3.

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor AJ, Trigg ME; Children's Cancer Group.

Blood. 2003 May 15;101(10):3809-17. Epub 2003 Jan 16.

4.

Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.

Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kühl J, Gadner H, Havers W, Plüss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H.

Klin Padiatr. 1998 Jul-Aug;210(4):192-9.

PMID:
9743952
5.
6.

Accumulation of methotrexate in systemic tissues after intrathecal administration.

Bleyer WA, Nelson JA, Kamen BA.

J Pediatr Hematol Oncol. 1997 Nov-Dec;19(6):530-2.

PMID:
9407940
7.

Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group.

Tsurusawa M, Katano N, Yamamoto Y, Hirota T, Koizumi S, Watanabe A, Takeda T, Hatae Y, Yatabe M, Mimaya J, Gushiken T, Nishi K, Anami K, Kikuta A, Kanegane H, Asami K, Nishikawa K, Sekine I, Kawano Y, Iwai A, Furuyama T, Ijichi O, Miyake M, Mugishima H, Fujimoto T, et al.

Med Pediatr Oncol. 1999 Apr;32(4):259-6.

PMID:
10102019
8.

Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy.

Cole PD, Zebala JA, Alcaraz MJ, Smith AK, Tan J, Kamen BA.

Cancer Chemother Pharmacol. 2006 Jun;57(6):826-34. Epub 2005 Sep 17. Erratum in: Cancer Chemother Pharmacol. 2006 Sep;58(3):418. Zebala, John A [added].

PMID:
16170572
9.

A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).

Bell BA, Brockway GN, Shuster JJ, Erdmann G, Sterikoff S, Bostrom B, Camitta BM; Pediatric Oncology Group study (now The Children's Oncology Group).

Pediatr Blood Cancer. 2004 Aug;43(2):105-9.

PMID:
15236274
10.

Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.

Maiguma T, Hayashi Y, Ueshima S, Kaji H, Egawa T, Chayama K, Morishima T, Kitamura Y, Sendo T, Gomita Y, Teshima D.

Int J Clin Pharmacol Ther. 2008 Nov;46(11):584-90.

PMID:
19000557
12.

Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia.

Wall AM, Gajjar A, Link A, Mahmoud H, Pui CH, Relling MV.

Leukemia. 2000 Feb;14(2):221-5.

PMID:
10673736
13.

Intrathecal methotrexate-induced acute chorea.

Necioğlu Orken D, Yldrmak Y, Kenangil G, Kandraloğlu N, Forta H, Celik M.

J Pediatr Hematol Oncol. 2009 Jan;31(1):57-8. doi: 10.1097/MPH.0b013e318190d434.

PMID:
19125090
14.

Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.

Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE.

Blood. 1999 May 1;93(9):2817-23.

15.

Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.

Seidel H, Andersen A, Kvaløy JT, Nygaard R, Moe PJ, Jacobsen G, Lindqvist B, Slørdal L.

Leuk Res. 2000 Mar;24(3):193-9.

PMID:
10739001
16.

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, Evans WE.

J Clin Invest. 1996 Jan 1;97(1):73-80.

17.

Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.

Winick NJ, Bowman WP, Kamen BA, Roach ES, Rollins N, Jacaruso D, Buchanan GR.

J Natl Cancer Inst. 1992 Feb 19;84(4):252-6.

PMID:
1734087
18.
19.

Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia.

Rubnitz JE, Relling MV, Harrison PL, Sandlund JT, Ribeiro RC, Rivera GK, Thompson SJ, Evans WE, Pui CH.

Leukemia. 1998 Aug;12(8):1176-81.

PMID:
9697870
20.

Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group.

Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A.

J Clin Oncol. 2009 Feb 20;27(6):897-903. doi: 10.1200/JCO.2008.18.1487. Epub 2009 Jan 12.

PMID:
19139435

Supplemental Content

Support Center